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ABSTRACT
Correlative studies from checkpoint inhibitor trials have indicated that better 
understanding of human leukocytic trafficking into the human tumor microenvironment 
can expedite the translation of future immune-oncologic agents. In order to directly 
characterize signaling pathways that can regulate human leukocytic trafficking 
into the tumor, we have developed a completely autologous xenotransplantation 
method to reconstitute the human tumor immune microenvironment in vivo. We 
were able to genetically mark the engrafted CD34+ bone marrow cells as well as the 
tumor cells, and follow the endogenous leukocytic infiltration into the autologous 
tumor. To investigate human tumor intrinsic factors that can potentially regulate the 
immune cells in our system, we silenced STAT3 signaling in the tumor compartment. 
As expected, STAT3 signaling suppression in the tumor compartment in these 
autologously reconstituted humanized mice showed increased tumor infiltrating 
lymphocytes and reduction of arginase-1 in the stroma, which were associated with 
slower tumor growth rate. We also used this novel system to characterize human 
myeloid suppressor cells as well as to screen novel agents that can alter endogenous 
leukocytic infiltration into the tumor. Taken together, we present a valuable method 
to study individualized human tumor microenvironments in vivo without confounding 
allogeneic responses.
INTRODUCTION
Durable clinical responses with immune checkpoint 
inhibitors recently have prompted an expansion of clinical 
trials with various combinations of immunomodulators 
for cancer patients [1, 2]. Clinical trials are frequently 
driven by correlative biomarker analyses that attempt to 
predict clinical responses based on expression of certain 
molecules in the human tumor microenvironment [3]. 
While these studies can yield potential discovery panels 
and possible selection criteria for the subsequent clinical 
trials, they provide a retrospective “snapshot” correlations 
and thus an incomplete mechanistic picture of the dynamic 
human tumor microenvironment. For mechanistic 
evaluations, preclinical testing of immunotherapeutic 
agents relies upon syngeneic immunocompetent murine 
models or genetically engineered mouse models (GEMM), 
which are limited by their inadequate genetic and 
biological representation of corresponding human cancers 
[4, 5]. Patient derived xenotransplant (PDX) models that 
introduce human tumor xenografts into immunodeficient 
mice that are reconstituted with human hematopoietic 
cells [6-8] are limited by the fact that the adaptive human 
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immune system developing in these mice is allogeneic to 
the tumor, even when the human thymus is concurrently 
implanted or when human HLA transgenic mice are 
used as recipients [9-11]. Thus, anti-tumor responses 
are dominated by alloantigen rather than tumor-specific 
antigen recognition. 
A method that can simultaneously reconstitute 
autologous human tumor and human immune cell in vivo 
would allow important immunological studies to expedite 
translation of immunotherapeutic trials. To partly address 
this problem, autologous T-cells have been adoptively 
transferred into a tumor bearing mice, but this exogenous 
method failed to account for other important non-
lymphocytic hematopoietic cells [12]. Others are currently 
generating murine lines with the different combinations 
of human HLA to overcome this allogeneic response 
but the polymorphism of HLA genes makes it virtually 
impossible to match all HLA alleles with a given tumor or 
transplanted immune system [13-15]. 
We describe here a system to reconstitute a 
fully autologous human tumor microenvironment that 
would allow direct studies of molecular pathways that 
can drive the relationship between tumor cells and the 
various components of hematopoietic cells. We use this 
system to analyze the immunological consequences 
of STAT3 signaling disruption on the human tumor 
microenvironment (TME). We demonstrate that genetic 
silencing of STAT3 in the human tumor compartment can 
mediate enhanced infiltration of human T cells into the 
developing human tumor in vivo. In addition, we used this 
novel system to characterize human myeloid suppressor 
cells, as well as to screen novel agents that can alter 
endogenous leukocytic infiltration into the tumor.
RESULTS
Autologous reconstitution of human tumors in 
vivo
We initially humanized NOD/SCID/γcnull HLA-A2+ 
(NOG-A2 crossed to human HLA-A0201 transgenic mice) 
mice that we generated with CD34+ enriched cells from 
cord blood from HLA-A2+ C-section specimens. These 
humanized NOG-A2 mice were found to repopulate 
both human lymphoid and myeloid hematopoietic cells 
(Supplemental Figure 1a). HLA-A2+ HNSCC tumors 
were initially xenotransplanted into these humanized 
mice to reconstitute the human HNSCC allogeneically, 
and we found that human T-cells can infiltrate into the 
tumor microenvironment (Supplemental Figure 1b). 
To bypass the allogeneic response in this system, we 
developed a completely autologous human tumor/
hematopoietic system using HNSCC surgical specimens 
and bone marrow cells (BMC) harvested during surgery. 
In brief, BMC and HNSCC tumor from HLA-A2+ patients 
undergoing composite surgical resection of HNSCC 
with reconstruction of the mandible with fibula bone 
were harvested. Primary tumor and CD34+ BMC from 
the fibula bone were initially engrafted into NOG-A2 
separately (Figure 1a). In the bone marrow engrafted mice, 
harvested hematopoietic cells in the spleen showed mature 
human lymphocytic and myeloid cells (Figure 1b). Tumors 
derived from the same patient as the donor BMC, which 
had been passaged in parallel to non-humanized NOG-A2 
mice, were then transplanted into the humanized mice to 
reconstitute a fully autologous tumor microenvironment 
(TME). When the transplanted tumor was analyzed, both 
human lymphoid and myeloid cells were found to infiltrate 
into the TME (Figure 1c). 
Typically, the chimerism of the hematopoietic 
system rates ranged from 70-90% as defined by human 
CD45 level with respect to total mononuclear cell from the 
spleen asmurine CD45 from the peripheral blood as shown 
in Figure 1b. Splenocytes also contained appropriate levels 
of human T-cells (CD4 and CD8), myeloid cells (CD11b 
and CD11c), and NK cells (NKG2D, NKp46). Poor 
engraftment was defined by global fragility of the mice 
in 2-86 weeks post transfer of BMC, and only healthy 
mice after 2 months were implanted with human tumor 
tissues. After engrafting approximately 110 mice with this 
method from 12 donors, 55% of the mice survived beyond 
6 weeks as shown in Supplemental Figure 2. It should be 
noted that many of these mice that did not survive beyond 
2 months received BMC from patients aged 70 or above, 
and we have stopped using fibula BMC from those over 
65 years old. With this optimization, all the mice survived 
to 2 months for tumor injection. While engraftments with 
cord blood was limited by the available abundance of 
CD34+ cells (104-5 per mouse), the greater abundance of 
fibular BMC allowed the transfer of 2 x105 CD34+ cells 
(per mouse) to allow comparable engraftment rates as 
with cord blood [16]. Unlike the implantation of PDX 
into non-humanized mice, most, if not all, of the mice 
had human HNSCC tissue growing in subcutaneous tissue 
for our analysis. Therefore, the “rate-limiting step” of 
this autologous reconstitution was the engraftment of the 
BMC step. Limited sources of patients undergoing fibular 
resections prevented titration of BMC engraftments on a 
per cell basis, but our global engraftment rates compared 
favorably with cord blood engraftments [16]. 
In order to ensure that the tumor infiltrating human 
T-cells are derived from the engrafted hematopoietic cells 
and not from the tumor infiltrating lymphocytes (TIL) 
from the tumor tissue, we labeled the human CD34+ 
BMC with lentiviral vectors that expressed GFP proteins. 
Once the engrafted lymphocyte progenitors were found 
to produce GFP positive lymphocytes in the peripheral 
blood (data not shown), autologous tumor was implanted, 
and the immunofluorescent microscopy clearly showed 
GFP+ immune cells in the TME with both lymphocytic 
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Figure 1: Human squamous cell carcinoma can be xenotransplanted into humanized mice autologously. a. Schematics 
of autologous reconstitution of HNSCC. b. After engraftment with CD34+ bone marrow cells from HNSCC patient undergoing 
surgery, humanized mice showed presence of human lymphocytic and myeloid cells (CD11b+), including quantifiable human NK cells 
(NKG2D+NKp46+) in the spleen. Gated mononuclear cells were plotted for human CD45 and murine CD45 levels (upper panels). Gated 
human CD45 then were plotted for human CD markers as noted in the axis (lower panels). In brief, peripheral blood was stained with 
murine CD45, human CD45, and   c. Surgical tumor specimens from the same patient whose CD34+ BMC were used to engraft NOG-A2 
mice (from 1b) were implanted into the same humanized mice. The engrafted tumor was harvested and stained for tumor infiltrating human 
CD8, CD4, and CD11b cells. The primary antibodies for these stainings were rabbit anti-human CD8, rat anti-human CD4, and rabbit anti-
human CD11b conjugated to Alexa Fluor® 568. The bar scale is 100µ. Upper left panel is an H&E stain of the same tumor.
Oncotarget2056www.impactjournals.com/oncotarget
and myeloid histology (Figure 2a - left lower panel). 
Immunohistochemical staining with human CD3 and 
CD11b conjugates co-localized to these GFP positive 
cells and confirmed the presence of both human lymphoid 
and myeloid cells in the TME (Figure 2a - right panels). 
While these experiments demonstrated that a significant 
proportion of T cells in the TME are derived from the 
engrafted BMC, they do not formally distinguish what 
proportion are from homeostatic expansion of mature T 
cells in the bone marrow vs. differentiation of CD34+ 
progenitor cells. When we probed the thymus from 
these mice, thymocytes from these engrafted mice were 
predominantly double positive human T-cells, suggesting 
that de novo development of human T cells in the murine 
thymus with human HLA-A2 expression was indeed 
operative (Figure 2b). Since we showed that human BMC-
derived cells from CD34+ grafts indeed reconstituted the 
murine thymic stroma, we reasoned that these T cells 
should be tolerant to the HLA-A2+ transplanted tumor 
that is seen in human tumor [17]. Lastly, we haplotyped 
the transplanted tumor and the human leukocytes from 
peripheral blood of these autologously humanized mice to 
validate that the HLA type was a complete match (Figure 
2c).
Humanized mice can generate CD4 dependent 
humoral responses
In order to assess the function of the adaptive 
immune system in these humanized NOG-A2 mice, 
they were vaccinated with KHL antigen and their CD4 
dependent generation of antibodies against KHL analyzed 
(Figure 3) [18]. Following immunization and 2 week 
booster with NDP23-KLH, serum levels of DNP specific 
human antibodies were quantitated with ELISA. These 
humanized mice generated increased IgG responses to all 
IgG subtypes, demonstrating that these mice can generate 
CD4 dependent humoral responses in vivo. 
STAT3 can mediate pro-carcinogenic human 
T-cell infiltration into human tumor to increase 
the growth rate in vivo
We previously found that STAT3 signaling in 
tumor cells can potentially decrease leukocyte migration 
in vitro [19]. When we specifically tested the migratory 
behavior of CD8+ T-cells from HNSCC cancer patients, 
we noted that STAT3 signaling in tumor cells can suppress 
lymphocytic migration in vitro. Conditioned media from 
HNSCC tumor cells did not induce T-cell migration, 
while media from same cell lines whose STAT3 gene was 
suppressed (“Stat3 knockout”) induced T-cell migration as 
much as our positive control treatment (“100% serum”)
(Figure 4a). We initially probed the TCGA for STAT3 
gene expression and phospho-STAT3 levels in our banked 
specimens (data not shown). However, while analyzing 
the transcript levels in the public cancer database such as 
TCGA and archived specimens may provide correlative 
support, [20], such methods cannot distinguish STAT3 
signaling in the tumor cells from the tumor infiltrating 
immune cells. With our ability to reconstitute the tumor 
tissue from the tumor cells and immune cells, we reasoned 
that our method can directly study lymphocytic trafficking 
mediated by tumor intrinsic STAT3 signaling in vivo. 
We initially started with an allogeneic HLA-A2+ 
HNSCC line (Cal27) transplanted into CD34+ BMC 
reconstituted NOG-A2 mice. Using STAT3 siRNA 
method, we silenced STAT3 signaling in Cal27 tumor 
cells and compared them with Cal27 transduced with 
control lentivirus. Despite the pleiotropic effect of STAT3, 
STAT3 silencing did not affect its growth rate in vivo when 
transplanted into an immunodeficient non-humanized 
NOG-A2 mice (Figure 4b - right panel). This demonstrated 
that STAT3 signaling in the tumor cells did not affect the 
immune cell independent apoptotic rate of the tumor in 
our system. However, in the context of a humanized mice, 
STAT3 silencing significantly decreased the growth rate of 
the reconstituted tumor (Figure 4b - left panel). When we 
compared the histology between the STAT3 silenced and 
control tumors, we noted increased tumor necrosis in the 
STAT3 silenced tissues (Figure 4c). When we quantitated 
the TILs using human CD45-fluorophore conjugate in 
IHC, STAT3 suppressed tumor cells showed increased 
tumor infiltrating human CD45 cells (Figure 4d - left 
panel). We confirmed that STAT3 expression was stably 
silenced after the tumors were harvested at the end of the 
in vivo experiments (Figure 4d - right panel). 
STAT3 can mediate pro-carcinogenic human 
immune cell infiltration into autologous human 
tumor to increase the growth rate in vivo
Since allo-antigen immune responses in the TME 
can confound the tumor growth rate in this allogeneic 
system, we tested the STAT3 signaling in primary HNSCC 
tumors using our autologous HNSCC tumor engraftment 
system. We silenced STAT3 signaling by transducing 
homogenized tumor cells between the serial passages 
in the non-humanized mice prior to the autologous 
reconstitution in the humanized mice. To ensure STAT3 
suppression in our system did not affect the apoptotic 
pathway, we injected these matched xenotransplants into 
non-humanized NOG-A2 mice and found no differential 
growth rates between the control scrambled siRNA vs 
STAT3 siRNA transduced tumors (Figure 5a - left). These 
matched tumors were then injected into mice humanized 
from BMC from the same cancer patient. In 3 of 4 human 
HNSCC specimen tested, STAT3 silencing significantly 
decreased the growth rate of autologously reconstituted 
tumor (Figure 5a - center). We harvested the tumors from 
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Figure 2: Autologously reconstituted human carcinoma is infiltrated with endogenous human hematopoietic 
lymphocytes that mature in the thymus. a. CD34+ BMC were transduced with lentivirus vectors containing GFP protein prior 
to BMC engraftment. Autologously reconstituted tumor was harvested, stained with DAPI, and immunofluorescent microscopy was 
performed. The left panels show tumor with only DAPI counterstain. Left upper panel is tumor xenografted into non-humanized mice, 
while the left lower panel is the tumor in autologously humanized mice (white arrowhead – lymphocyte; white arrow – myeloid cells). 
Slides were also co-stained with human CD3 and CD11b conjugates (right panels). The bar scale is 100µm. b. Human lymphocytes from 
humanized NOG-A2 (HLA-A0201 transgene) mice mature in the thymus. RBC depleted peripheral blood (PBL) from humanized mice 
were stained with hCD4 and hCD8. Thymus from these humanized mice were harvested and stained for hCD4 and hCD8. c. After tumors 
grew to 1 cm3 in autologously humanized mice, splenocytes and tumor were harvested for human HLA class I and class II typing. CD3 
depletions were performed on the tumor specimens prior to this analysis. The haplotype report showed that human HLA class I and class II 
types between the tumor and the immune cells were identical. . 
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these experiments and probed for pSTAT3 signaling, and 
noted persistent STAT3 suppression at the end of 35 days 
in the STAT3 siRNA treated mice (Figure 5a - right). In 
some of the experiments, we noted no tumor engraftment 
in the non-humanized mice. As shown in these autologous 
experiments, we did note variability in the tumor growth 
rates. For those mice that failed to grow tumors, we could 
not analyze their STAT3 suppression levels.
In mice with appropriate tumor engraftment, we 
probed the TME for leukocyte infiltrations between the 
STAT3 suppressed group and the control group (Figure 
5b and 5c). In the STAT3 suppressed reconstitution, both 
myeloid and lymphoid cells were noted to be increased. 
We also stained the tissue for human arginase-1 that is 
transcriptionally upregulated with STAT3 [21], and we 
found dramatic reduction of this immunosuppressive 
enzyme in the STAT3 suppressed tumor. In brief, our 
autologous system has allowed the direct testing of tumor 
endogenous factors that can mediate not only the tumor 
trafficking of human immune cells, but also the metabolic 
microenvironment of the tumor tissue. 
Autologously reconstituted human tumor can be 
used to study immunosuppressive myeloid cells
While our previous studies were focused on the 
T-cells, we inquired whether the myeloid population can 
also be studied in our model. Since human HNSCC can 
expand the MDSC population, we harvested the spleen 
in these autologous human tumor bearing humanized 
mice and sorted human MDSC as described before 
and tested their ability suppress human T-cells. Our 
previous work with murine myeloid suppressor cells 
suggested that the monocytic MDSC represent the more 
potent T-cell suppressor [22], so we hypothesized that 
the human MDSC may have similar activity. We sorted 
CD11b+CD14+DRlow as well as CD11b+CD15+DRlow from 
these mice and compared their T cell suppression activity. 
Consistent with our previous work in the murine system, 
we found that the monocytic CD14+ MDSC from these 
human tumor bearing humanized mice can suppress 
human T-cell activation ex vivo while the granulocytic 
CD15+MDSC failed to demonstrate this (Figure 6a) [22]. 
We titrated these MDSC with different ratios of human 
T-cells, and their suppressive activity was comparable to 
the MDSC from HNSCC patients (Supplemental Figure 
2).
Humanized mice reconstituted with autologous 
human tumor can be used to assess the 
activity of intra-tumoral injection of novel 
immunomodulatory agents
As a scalable in vivo system, our method is also 
amenable for testing immunotherapeutic agents in a late 
Figure 3: Autologously xenotransplanted mice can mount a T-cell dependent antibody response in vivo. After vaccination 
and boost with DHP-KLH, serum levels of DNP specific human IgG1-4 in DNP-KLH immunized mice were measured using ELISA in 
triplicate samples. All these representative figures are from independent experiments performed from three tumor bearing humanized and 
three non-tumor bearing non-humanized mice (NOG-A2).
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preclinical phase as well as in parallel to clinical trials. To 
test our system for novel immunotherapeutic adjuvants, 
we treated these autologously reconstituted human tumors 
with intra-tumoral synthetic cyclic dinucleotide, ML-RR-
CDA, currently being tested in a Novartis phase I clinical 
trial [23]. Compared to PBS controls, intra-tumoral ML-
RR-CDA induced a potent Th1 (IFNγ) response in the 
tumor microenvironment that resulted in an in vivo anti-
tumor response of the reconstituted human HNSCC tumor 
(Figure 6b). These results were comparable to the efficacy 
of ML-RR-CDA in murine tumor models tested previously 
[24]. 
DISCUSSION
The translational limitations of genetically 
engineered murine models were recently reviewed 
[25]. While patient derived xenograft system in 
immunodeficient mice may recapitulate some of the 
genetic diversity and heterogeneity of human tumors for 
personalized cancer research of signaling pathways of the 
tumor cells, it cannot be used to study immunotherapeutic 
modalities that are now establishing itself as an important 
aspect of clinical oncology in most forms of human 
cancer [26-28]. Genetically engineered models also have 
limitations for preclinical testing of immunomodulating 
agents since some of the phenotypes derived from 
genetic manipulations may minimize the stromal and 
the immunological context of the autochthonous tumor 
[25]. Although xenografts into humanized models are 
being used to study the immunological responses to 
the transplanted tumor, an important limitation is the 
unavoidable allogeneic responses that may confound 
the anti-tumor responses seen in these mice. Autologous 
adoptive transfer of T cells was recently demonstrated, 
but this method does not allow for endogenous immune 
infiltration into the developing tumor [12]. Our autologous 
system alleviates these problems and provides a method 
to study endogenous lymphocytic and myeloid cell 
trafficking into the human tumor in vivo. 
Using our autologous model, we were able to 
genetically modify STAT3 signaling in the tumor 
compartment and demonstrate its ability to regulate the 
tumor infiltrating human lymphocytes that can promote 
the tumor growth rate [19, 29]. We also demonstrated our 
ability to genetically modify the human hematopoietic 
cells, so we now have the capability of studying the 
human tumor-immune cells relationships in vivo, both in 
an allogeneic and an autologous system (Figure 2A). Since 
this system is completely autologous, any observed in vivo 
effect can be attributed to the experimental interventions 
rather than the allogeneic response that is inherent in 
the current PDX systems. Moreover, rather than relying 
on correlative relationships from specimens, we can 
now directly test specific immune-oncologic signaling 
pathways in the human TME in vivo to complement 
mechanistic studies on genetically engineered murine 
tumor systems [42]. Furthermore, our autologous platform 
also allows future study of human T-cells against tumor 
neoantigen development in a preclinical setting with the 
recent advances in TCR sequencing technology [30]. 
Lastly, our method can also be used to develop rare tumor 
models that do not have syngeneic murine models for 
preclinical developments of novel immune-oncologic 
agents. 
In multiple series of immune checkpoint blockade 
trials, there has been a consistent demonstration that 
enhanced lymphocytic infiltration has been associated 
with improved clinical responses [31-33]. Towards 
the goal of targeting the adaptive immune resistance 
mechanism of the developing tumor, we and other authors 
previously noted that tumor cell STAT3 signaling can 
potentially regulate the leukocytic infiltration into the 
TME as part of its pleiotropic carcinogenic effects in 
murine models [19, 34, 35]. To the extent that STAT3 
signaling mediates immunomodulatory effect within the 
TME, our experiments support future STAT3 clinical trials 
that combine immune checkpoint inhibitors with inhibitors 
of STAT3 signaling [34, 36-38]. In fact, a recent study has 
reported promising clinical results with STAT3 inhibition 
[39]. 
While our reconstitution system has yet to 
Figure 4: STAT3 signaling in the human tumor cells can mediate human T-cell trafficking into the tumor in vivo to 
increase the tumor growth rate in an allogeneic reconstitution system. a. Lymphocytes from HNSCC patients undergoing 
surgery were harvested and assayed for migration towards conditioned supernatants from Cal27 tumor cell lines in this chemotaxis assay 
(5 experiments performed in triplicates) [19]. Negative controls consisted of media with no exposure to tumor cells (“no treatment”), and 
100% serum as positive controls. Cal27 cells were transduced with scrambled lentivirus (“tumor cells”) or STAT3 siRNA lentivirus (“Stat3 
knockout”). b. HLA-A2+ Cal27 HNSCC cell lines were transduced with either scrambled siRNA or STAT3 siRNA, and these tumor 
cells were injected into humanized mice (7-10 mice/group). Growth rates were followed after xenotransplantation (left panel, *P<0.01). 
These tumor cells were also injected into non-humanized NOG-A2 mice (right panel). These experiments were independently repeated 3 
times. c. Harvested tumors were stained with H&E and analyzed. The bar scale is 100µ. d. Tumor transduced with STAT3 siRNA showed 
greater number of tumor infiltrating human CD45+ cells (left panel). Harvested tumor from the two groups of tumor from humanized mice 
(scrambled siRNA control and siRNA treated Cal27) were stained with human CD45-Alexa Fluor 568 conjugate and CD45+cells were 
counted over 10 fields and averaged. We also ensured that transduced tumor cells had stable suppression of STAT3 at the time of tumor 
harvest (right panel) by performing pSTAT3 expression analysis in the two groups of tumors from Fig. 4b at the time of tumor harvest on 
day 36. The bar scale is 100µ.
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Figure 5: Tumor intrinsic STAT3 signaling that can regulate human leukocytic infiltration and immunosuppression can 
direct tumor growth in vivo in an autologous system.  a. Patient derived  tumors were transduced with siRNA lentivirus (scrambled 
or STAT3 siRNA) and autologously implanted into humanized mice and non-humanized mice. Shown are autologous reconstitution from 
4 donors. Autologously reconstituted HNSCC tumor with STAT3 suppression had decreased tumor growth rate (center panels) while the 
matched PDX in non-humanized mice demonstrated no differential tumor growth rates (left panels). Four experiments were performed with 
4-5 mice per group. Harvested tumor from each group had persistant STAT3 suppression at the end of the experiment (right panels). For 
some xenoplants, the tumor did not engraft as demonstrated, particularly in non-humanized mice (autolog 3, 4). (Red – scrambled siRNA, 
Blue – STAT3 siRNA, Green – untreated tumor)(**, p<0.01;  *, p<0.05). b. Tumor STAT3 signaling altered the infiltrating immune cells as 
well as the metabolic milieu of the TME. Harvested tumor were stained with human leukocyte markers and human arginase-1 antibodies 
with immunofluorescence. c. For hCD4 and hCD8 staining, positive cells were quantitated in 10 randomly selected different fields at 40x 
magnification. The bar scale is 100µ. STAT3 suppressed tumor tissue showed increased tumor infiltrating human CD4 and CD8 T-cells..
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Figure 6: Autologously reconstituted HNSCC tumor system can be used to study human myeloid derived suppressor 
cells as well as novel immunomodulatory agents. a. Splenocytes from autologously reconstituted human tumor bearing mice were 
harvested, and CD11b+CD14+DRlow (CD14) and CD11b+CD15+DRlow (CD15) cells were sorted to homogeneity to ensure monocytic and 
granulocytic histology (data not shown)[21]. Human CD3+ cells were co-cultured with CD11b+CD14+HLA-DRlow and CD11b+CD15+HLA-
DRlow cells in complete RPMI media and stimulated (Sti) with PMA/Ionomycin. CD3+IFNγ+ cells were quantitated with flow cytometry 
as the measurement of T-cell suppression when mixed with MDSC. b. Palpable tumors of equivalent size in both groups were treated 
intratumorally with either PBS control or ML-RR-CDA at 20µg per injection and the tumor growth was followed. Experiment repeated 
twice with 4-5 mice per group. At the completion of experiment, the tumor was harvested and stained with human CD8, IFNγ, and DAPI 
counterstain (right panels). The bar scale is 100µ.
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account for the mesenchymal cells of the tumor 
microenvironment, there are several biomedical 
implications from our autologous reconstitution of the 
human tumor in vivo. Since bone marrow aspiration for 
autologous xenotransplantation is clinically feasible with 
minimal risks at the time of surgery, routine autologous 
reconstitution of an individual tumor in a humanized 
system is now possible. This system substantially increases 
the personalization of cancer treatment whereby immune-
oncologic treatment of an individual tumor can be studied 
in the context of their own tumor microenvironment. 
These methods also allow the screening and testing of 
immunotherapeutic agents that have gained prominence 
since the introduction of immune checkpoint inhibitors 
into the clinic [40, 41]. 
MATERIALS AND METHODS
Reagents, cells, mice
Antibodies against anti-human CD3, CD4, CD8, 
CD11c, CD11b, CD14, CD15, CD16, CD19, CD33, 
CD34, CD45, CD56, NKP46, CD123, arginase-1, 
neutrophil lipocalin, IFNγ, HLA-DR, and pStat3 
were purchased from BD Biosciences, Biolegend, or 
ebiosciences. Synthetic 2’-5’ linked [R,R] dithio cyclic 
di-AMP (ML-RR-CDA) was a gift from Aduro Biotech. 
NOD.scid.IL2Rγcnull (NOG) mice were crossed to NOD.
HLA-A2*0201 transgenic mice (Jackson) to generate 
NOD/SCID/γcnull HLA-A2+ (NOG-A2) mice in our lab 
and housed according to JHH Animal Care. In some 
cases, HSCFTL mice [NOD-Cg-PrKdcscidIL2γgtm1sug/
JicTac mice engrafted with human CD34+ hematopoietic 
stem cells (HSCs) (Taconic), NSG, or NSG-HLA-A2.1 
mice (Jackson) were used. Human CD34 microbead kit 
and pan T-cell isolation kit were purchased from Miltenyi 
Biotec. Human HNSCC cell lines used consisted of Cal27 
and SCC25 (ATCC). The cell lines were authenticated 
by a short tandem repeat profiling analysis using the 
AmpFISTR Identifier PCR Amplification kit (Applied 
Biosystems) at the Genetic Resources Core Facility, JHH 
[43]. Cells were maintained in DMEM medium typically 
supplemented with 10% FBS and penicillin (100 U/
mL) and streptomycin (100 mg/mL) and maintained in a 
humidified incubator at 37°C in a 5% CO2 atmosphere. 
TCGA transcriptome analysis
STAT3 gene expression levels (n = 279) were 
obtained from The Cancer Genome Atlas dataset based 
on methods described in the Supplementary Materials 
[20]. A two-sided Wilcoxon rank sum test was used to 
assess the difference in the expression levels between the 
mesenchymal and classical subtypes.
TCGA RPPA analysis
Phosphorylated STAT3 expression levels (n = 
200) were obtained from The Cancer Genome Atlas 
dataset. Briefly, the protein lysates from frozen tumors 
were prepared and analyzed by reverse phase protein 
array (RPPA) as previously published [44, 45]. The 
primary antibody, phospho-STAT3-Tyr705 (Cell 
Signaling Technology), was stained at 1:500 dilutions. 
The difference in the expression levels between the 
mesenchymal and classical subtypes was assessed using 
a two-sided Wilcoxon rank sum test. 
Engraftment of hematopoietic stem cells
8-10 weeks NOG-A2, NOG, NSG, or NSG-
HLA-A2.1 mice were lethally irradiated with 4-5 Gray 
prior to tail vein injection with human umbilical cord blood 
cells (CBC) or human bone marrow CD34+ hematopoietic 
stem cells after 1:2 dilution with PBS/1%FBS and passed 
cells through 100µm cell strainer (Corning). Typically, 
the CBC and bone marrow cells (BMC) were fractionated 
with density-gradient Ficoll-Hypaque. The buffy coat 
layer cells were washed twice with PBS/1% FBS, and 
CD34+ cells were positively selected with Miltenyi 
column. 5x104-2x105 CD34+ cells in 500µl PBS were 
used to humanize lethally irradiated mice. In some cases, 
these CD34+ BMC were transduced with high titer GFP 
lentivirus prior to transfer. Peripheral blood or spleen were 
analyzed for engraftment of human hematopoietic cells 
after 6 weeks.
Autologous and allogeneic reconstitution of tumor
For autologous reconstitution, tumor specimen 
and fibular bone marrow cells from HLA-A2+ patients 
undergoing head and neck cancer surgery were harvested. 
BMC were used to engraft NOG-A2 mice as noted 
above. In parallel to this engraftment, the tumor tissue 
(approximately 0.125cm3) from the same patient were cut 
and digested in media containing DNAse I (Roche) and 
Liberase Blendzyme 2 (20,000 Mandl U/ml) (Roche) 20 
minutes at room temperature. The digested tumor tissue 
was passed through 100µm cell strainer and washed with 
PBS/1%FBS. 1-2x106 tumor cells mixed with BD Matrigel 
TM basement membrane matrix (BD Bioscience) in 100µl 
PBS. These cells were subcutaneously injected initially 
into non-humanized NOG-A2 mice. Once the mice 
engrafted with their matched BMC were confirmed to 
have CD4+ and CD8+ T-cells in the peripheral blood, the 
matched tumor tissue was implanted subcutaneously into 
the bone marrow engrafted humanized NOG-A2 mice. In 
some cases, the tumor cells were transduced with STAT3 
or control siRNA lentivirus prior to xenotransplantation. 
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For allogeneic reconstitution, HLA-A2+ tumor cell lines 
were injected subcutaneously into humanized NOG-A2 
mice from allogeneic BMC or CBC. 
STAT3 silencing with lentivirus and editing via 
CRISPR
Transfections of tumor cells (both primary and tumor 
cell lines) with STAT3 small interfering RNA (siRNA) 
oligonucleotide (Santa Cruz) were conducted using 
LipofectAMINE 2000 (Invitrogen Life Technologies). 
For control samples, cells were transfected with scrambled 
small interfering RNA oligonucleotide or LipofectAMINE 
alone. The cells were transfected with 15nM of STAT3 
or scrambled siRNA and cultured for two days. Mission 
TRC-Hs (Sigma) clone sets of sequence-verified siRNA 
lentiviral plasmids were obtained from the JHU High 
Throughput Biology Center. VSV-G pseudo-typed 
virus was produced by the Johns Hopkins Neurosurgery 
Vector Core by co-transfecting 293T cells with an siRNA 
transducing vector and two packaging vectors: psPAX2 
and PMD2.G [19]. In some cases, STAT3 was edited 
using CRISPR/CAS9 kit was purchased from Origene 
(KN204922) containing GFP reporter gene. Human Cal27 
cells were seeded to reach 50-70% confluency day a 
before transfection. The scramble control DNA and STAT3 
gRNA vector with donor DNA were transfected into Cal27 
cells separately. After 2-5 passages the GFP positive cells 
were sorted. Additionally, GFP+ cells were selected with 
puromycin 1-2µg/ml for purity, whereas western blots 
were applied to confirmed complete STAT3 knockout or 
silencing in transfected cells.
Tumor treatment assay
Humanized mice were subcutaneously injected 
with 106 Cal27 human squamous cells or serially passaged 
patient derived tumor tissue. In some series, the tumor 
cells were infected with lentivirus as noted above for 
STAT3 silencing/editing. Once palpable tumors developed 
(20-30 days), 20µg ML-RR-CDA (in 100µl PBS)(Aduro) 
was injected intra-tumorally twice over 1 week period 
in therapeutic experiments with adjuvants. The control 
groups were injected with PBS alone. For all these 
experiments, 3-5 mice were used per group. Palpable 
tumor measurements were initiated once all 3 dimensions 
reached anywhere from 2-4 mm. Relative tumor volume 
V was calculated using the formula V = (W2 X L)/2, 
where L is the longest and W is the shortest diameter. 
Tumor growth was monitored every alternate day and 
animals were euthanized when tumors reached 15-20 mm 
in diameter. 
Flow cytometry
Peripheral blood and spleen was collected from 
humanized mice. The white blood cells were isolated 
using Ficoll-paqueTM plus (GE Healthcare) in a ratio of 
2:1. CD4, CD8, CD3, CD45, CD11b, CD11c, CD56, 
CD16, NKP46, CD123, CD33, HLA-DR staining were 
determined by flow cytometry (FACSCalibur) and 
analyzed with FloJo software (Tree Star). For pStat3 
(pY705) staining, tumor was harvested and CD45 depleted 
tumor cells were fixed in 2% paraformaldehyde/PBS for 
10 min at 37°C and permeabilized by resuspending with 
vigorous vortexing in 500 µl ice-cold 90% methanol per 
106 cells and incubated at 4°C for 30 min on ice. After 
PBS washing and resuspension, cells were stained with 
Alexa Fluor 647-conjugated phospho-STAT3 antibody 
(BD Biosciences) for 1 hour at RT.
Immunohistochemistry
10µm thick frozen sections were fixed with acetone, 
and blocked with 1% BSA for 30 minutes at RT. For 
paraffin embedded tissue, the sections were fixed in 
4% paraformaldehyde prior to 1% BSA blocking as 
noted above. Anti-human CD4 and CD8 FITC (green) 
conjugates or anti-human CD4, CD8, CD45, arginase-1, 
neutrophil lipocalin primary antibodies were incubated 1 
hour and 4oC. For human CD45, arginase, and neutrophil 
lipocalin primary antibodies, Cy3 (red) conjugate antibody 
was used as secondary antibody in some cases. DAPI 
was used as the nuclear counterstain. Positive cells in 
10 randomly selected fields at x40 magnification were 
quantitated. The microscope was Nikon, Eclipse E800, 
and the photos were captured with Nikon DS-Qi1Mc 
camera with NIS-Element AR 3.0 software.
MDSC T-cell suppression assay
Human CD14+HLA-DR-/lo, CD15+HLA-DR-/lo and 
CD3+ cells were sorted from tumor bearing humanized 
mice spleen. Human CD3+ cells were co-cultured with 
CD14+HLA-DR-/lo and CD15+HLA-DR-/lo cells in complete 
RPMI media. After the cells were stimulated with 1mM/
ml PMA and 1mg/ml Ionomycin and Golgistop for 4.5 
hrs, harvested cells were performed membrane and 
intracellular cytokine staining with Cytofix/Cytoperm 
reagent kit (BD Biosciences). FACS data was collected on 
a FACSCalibur and was analyzed with FlowJo software 
(Tree Star). In some cases, stimulated T-cell proliferation 
was measured after 72 hours using 3H-thymidine 
incorporation. CD4+ T cells from humanized mice were 
isolated during the sorting of MDSC in parallel and 
activated using αCD3 and αCD28 (eBioscience) in some 
cases. MDSC or HLA-DR+ controls were co-cultured 
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with autologous T cells at different (T cell:MDSC) ratios 
as noted in the figure legends. T-cell suppression assays 
were performed with 3% FCS in RPMI-1640. 
ELISA
Humanized mice were immunized with 2, 
4-dinitrophenyl hapten-keyole limpet hemocyanin (DNP23-
KLH, Biosearch Technologies) 0.1mg/mouse followed 
by a booster shot 3 weeks later. After 2 weeks the levels 
of DNP-specific humanized mice serum human IgG and 
its subclass antibodies were measured by enzyme-linked 
immunosorbent assay (ELISA, Life Technologies). 
Statistics
We used paired t-test to calculate two-tailed p 
values to estimate the statistical significance of differences 
between two treatment groups using Excel software. Error 
bars are standard error of means. P values are labeled in 
the figures. Kaplan-Meier curves were generated using 
GraphPad Prism software and analyzed with log-rank test. 
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